This third edition volume expands on the previous editions with new topics that cover drug discovery through translational bioinformatics, informatics, clinical research informatics, as well as clinical informatics. The chapters discuss new methods to study target identification, genome analysis, cheminformatics, protein analysis, and text mining.
TiD News: May
This third edition volume expands on the previous editions with new topics that cover drug discovery through translational bioinformatics, informatics, clinical research informatics, as well as clinical informatics. The chapters discuss new methods to study target identification, genome analysis, cheminformatics,
The SBIR was awarded to a company commercializing G-1, a GPER agonist co-developed by: Cristian Bologa, Larry Sklar, Eric Prossnitz and Tudor Oprea.
Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced it has been awarded a Phase 2 Small Business Innovation Research (“SBIR”) Award by the National Cancer
Virtual screening is a well-established technique that has proven to be successful in the identification of novel biologically active molecules, including drug repurposing. Whether for ligand-based or for structure-based virtual screening, a chemical collection needs to be properly processed prior
Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacy
Read Article Newly observed KD occurred in 14,713 patients. No regimen had significantly lower risk of KDs than “No drug”. The HR estimates ranged 0.86–2.66 for “all” KDs and 0.87–5.30 for “severe” KDs. As additional drugs were combined to compare
Here you can search Publications by Author. Tudor Oprea, M.D., Ph.D. Cristian Bologa Ph.D. Browse Our Latest Publications. Pharos: Collating protein information to shed light on the druggable genome. Nguyen DT, Mathias S, Bologa C, Brunak S, Fernandez N, Gaulton A,
Bioinformatics and Drug Discovery 3rd Edition, Editors: Dr. Larson & Dr. Oprea Buy on Amazon Dr. Kroth’s Book Available! Health Care USA, Ninth Edition. Dr. Lambert’s book available, “Human Genome Informatics”. Human Genome Informatics: Translating Genes into Health examines the
DrugCentral is online drug information resource created and maintained by Division of Translational Informatics at University of New Mexico. DrugCentral provides information on active ingredients chemical entities, pharmaceutical products, drug mode of action, indications, pharmacologic action. We monitor FDA, EMA,
Drug Repurposing Projects Ketorolac Virtual screening by TiD identified the R-enantiomer of ketorolac as a hit for blocking GTPase activation in response to growth factor stimulus. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief under the trade
FACILITIES AND OTHER RESOURCES UNIVERSITY OF NEW MEXICO Translational Informatics Division The Translational Informatics Division (TID) is housed in the Innovation Discovery & Training Complex (IDTC) together with the UNM Center for Molecular Discovery (UNMCMD). TID is part of the
Cheminformatics is the application of informatics and computation to chemistry. Historically, cheminformatics has been associated with drug discovery science. Cheminformatics encompasses a wide range of foundational disciplines and computational technologies, from graph theory based molecular representations, to machine learning based
Translational Bioinformatics (TBI): The science of leveraging biomolecular data into clinical medicine. Here is a much longer definition from the American Medical Informatics Association site. Translational Bioinformatics is the development of storage, analytic, and interpretive methods to optimize the transformation of increasingly
Fellowship NOW Being Offered at UNM The Department of Internal Medicine is starting a new Clinical Informatics Fellowship. For more information, click HERE Clinical Informatics is the application of health information technologies to help in the quality of health care, control
TiD Twitter Feed
The goal of the Illuminating the Druggable Genome (IDG) program is to improve our understanding of the properties and functions of proteins that are currently unannotated within the three most commonly drug-targeted protein families: G-protein coupled receptors, ion channels, andRead more
Please click on images to the right to learn more about some of TiD's innovative applications such as the recently developed TiNEX, our legacy Public Apps, and Carlsbad One. For more TiDware, see the tab at the top of this page.